NEW YORK (GenomeWeb News) – T-cell-based diagnostics development firm Lophius Biosciences today announced the closing of a financing round that brought in €4 million ($5.3 million) in funding.

Lophius will use the cash infusion to launch its technologies, it said. VRD and WIC were new investors in the round. Existing investors include S-Refit, HighTech Gründerfonds, Bayern Kapital and two angel investors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.